Mayne Pharma Group Limited (MYX.AX)

AUD 4.85

(-2.02%)

Long Term Debt Summary of Mayne Pharma Group Limited

Mayne Pharma Group Limited's latest annual long term debt in 2024 was 31.64 Million AUD , up 11.1% from previous year.
Mayne Pharma Group Limited's latest quarterly long term debt in 2024 FY was 31.64 Million AUD , up 11.1% from previous quarter.
Mayne Pharma Group Limited reported annual long term debt of 28.48 Million AUD in 2023, up 402.03% from previous year.
Mayne Pharma Group Limited reported annual long term debt of 5.67 Million AUD in 2022, down -98.02% from previous year.
Mayne Pharma Group Limited reported quarterly long term debt of 31.64 Million AUD for 2024 FY, up 11.1% from previous quarter.
Mayne Pharma Group Limited reported quarterly long term debt of 31.64 Million AUD for 2024 Q4, down 0.0% from previous quarter.

Annual Long Term Debt Chart of Mayne Pharma Group Limited (2024 - 2007)

Historical Annual Long Term Debt of Mayne Pharma Group Limited (2024 - 2007)

Year	Long Term Debt	Long Term Debt Growth
2024	31.64 Million AUD	11.1%
2023	28.48 Million AUD	402.03%
2022	5.67 Million AUD	-98.02%
2021	285.8 Million AUD	-17.02%
2020	344.42 Million AUD	8.14%
2019	318.5 Million AUD	-14.86%
2018	374.11 Million AUD	14.39%
2017	327.03 Million AUD	329.39%
2016	76.16 Million AUD	25.32%
2015	60.77 Million AUD	33.12%
2014	45.65 Million AUD	16.39%
2013	39.22 Million AUD	0.0%
2012	- AUD	0.0%
2011	- AUD	-100.0%
2010	1.02 Million AUD	0.0%
2009	- AUD	-100.0%
2008	2222.00 AUD	-60.01%
2007	5556.00 AUD	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q2	30.01 Million AUD	0.0%
2024 FY	31.64 Million AUD	11.1%
2024 Q4	31.64 Million AUD	0.0%
2023 FY	28.48 Million AUD	402.03%
2023 Q4	28.48 Million AUD	0.0%
2023 Q2	4.33 Million AUD	0.0%
2022 Q2	326.69 Million AUD	0.0%
2022 Q4	5.67 Million AUD	0.0%
2022 FY	5.67 Million AUD	-98.02%
2021 Q2	279.99 Million AUD	0.0%
2021 Q4	285.8 Million AUD	0.0%
2021 FY	285.8 Million AUD	-17.02%
2020 FY	344.42 Million AUD	8.14%
2020 Q4	344.42 Million AUD	0.0%
2020 Q2	333.78 Million AUD	0.0%
2019 Q2	337.77 Million AUD	0.0%
2019 FY	318.5 Million AUD	-14.86%
2019 Q4	318.5 Million AUD	0.0%
2018 Q2	359.08 Million AUD	0.0%
2018 Q4	374.11 Million AUD	0.0%
2018 FY	374.11 Million AUD	14.39%
2017 Q2	313.07 Million AUD	0.0%
2017 FY	327.03 Million AUD	329.39%
2017 Q4	327.03 Million AUD	0.0%
2016 Q4	76.16 Million AUD	0.0%
2016 FY	76.16 Million AUD	25.32%
2016 Q2	64.79 Million AUD	0.0%
2015 FY	60.77 Million AUD	33.12%
2015 Q2	50.68 Million AUD	0.0%
2015 Q4	60.77 Million AUD	0.0%
2014 Q2	49.31 Million AUD	0.0%
2014 Q4	45.65 Million AUD	0.0%
2014 FY	45.65 Million AUD	16.39%
2013 Q4	39.22 Million AUD	0.0%
2013 Q2	39.24 Million AUD	0.0%
2013 FY	39.22 Million AUD	0.0%
2013 Q3	39.22 Million AUD	-0.04%
2012 FY	- AUD	0.0%
2012 Q4	- AUD	0.0%
2011 Q4	- AUD	0.0%
2011 FY	- AUD	-100.0%
2010 Q4	1.02 Million AUD	0.0%
2010 FY	1.02 Million AUD	0.0%
2009 Q4	- AUD	0.0%
2009 FY	- AUD	-100.0%
2008 FY	2222.00 AUD	-60.01%
2008 Q4	2222.00 AUD	0.0%
2007 Q4	5556.00 AUD	0.0%
2007 FY	5556.00 AUD	0.0%

Peer Long Term Debt Comparison of Mayne Pharma Group Limited

Name	Long Term Debt	Long Term Debt Difference
Firebrick Pharma Limited	- AUD	-Infinity%